Coastline Trust Co lowered its holdings in Becton Dickinson and Co (NYSE:BDX) by 1.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,340 shares of the medical instruments supplier’s stock after selling 328 shares during the quarter. Becton Dickinson and accounts for about 0.8% of Coastline Trust Co’s investment portfolio, making the stock its 26th largest position. Coastline Trust Co’s holdings in Becton Dickinson and were worth $5,398,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BDX. Bath Savings Trust Co raised its holdings in Becton Dickinson and by 12.5% during the second quarter. Bath Savings Trust Co now owns 27,899 shares of the medical instruments supplier’s stock worth $7,031,000 after purchasing an additional 3,107 shares in the last quarter. Thomasville National Bank grew its position in shares of Becton Dickinson and by 5.3% during the second quarter. Thomasville National Bank now owns 1,667 shares of the medical instruments supplier’s stock worth $420,000 after acquiring an additional 84 shares during the last quarter. Baystate Wealth Management LLC grew its position in shares of Becton Dickinson and by 39.0% during the second quarter. Baystate Wealth Management LLC now owns 449 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 126 shares during the last quarter. Private Asset Management Inc. grew its position in shares of Becton Dickinson and by 2.0% during the second quarter. Private Asset Management Inc. now owns 2,532 shares of the medical instruments supplier’s stock worth $638,000 after acquiring an additional 50 shares during the last quarter. Finally, Summit Financial Group Inc. purchased a new position in shares of Becton Dickinson and during the second quarter worth approximately $208,000. 84.23% of the stock is currently owned by hedge funds and other institutional investors.

In related news, SVP Charles R. Bodner sold 1,514 shares of Becton Dickinson and stock in a transaction on Friday, September 6th. The shares were sold at an average price of $260.08, for a total value of $393,761.12. Following the transaction, the senior vice president now directly owns 5,180 shares in the company, valued at approximately $1,347,214.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James C. Lim sold 1,929 shares of Becton Dickinson and stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,249 shares of company stock worth $9,616,803. 0.12% of the stock is currently owned by insiders.

Shares of BDX opened at $258.59 on Friday. The company’s 50 day simple moving average is $254.23 and its 200-day simple moving average is $246.15. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $264.74. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The firm has a market cap of $69.32 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 1.64 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same period last year, the firm posted $2.91 EPS. Becton Dickinson and’s quarterly revenue was up 1.7% on a year-over-year basis. As a group, equities research analysts forecast that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a $0.77 dividend. The ex-dividend date was Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.19%. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Co raised their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. Morgan Stanley raised their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Piper Jaffray Companies lowered their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Finally, Raymond James raised their target price on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 28th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $266.55.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Range Trading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.